Ladenburg initiated coverage of Acrivon Therapeutics with a Buy rating and $22 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACRV:
- Acrivon Therapeutics initiated with a Buy at H.C. Wainwright
- Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Acrivon Therapeutics expects cash to fund operations into 4Q24
- Acrivon Therapeutics reports Q4 EPS (80c) vs. ($2.45) last year
- Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference